OCA
VINC

Octagon Capital Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Octagon Capital Advisors’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$5.06M – 59
2024
Q1 		$5.06M Buy
+50,000
New +$3.16M 0.61% 36

Other funds holding VINC

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Octagon Capital Advisors's VINC Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2024, closing a stake of 50,000 shares — an estimated $5.06M sold.

Octagon Capital Advisors first reported a position in VINC in Q1 2024 and held it in 1 quarter. The position peaked at $5.06M in Q1 2024. 27 funds tracked by Wall St. Rank hold VINC as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 50,000 Vincerx Pharma, Inc. Common Stock shares in Q2 2024, an estimated $5.06M.
  • Octagon Capital Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $5.06M in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.